NCT02088112View on ClinicalTrials.gov

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

PHASE1CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

March 24, 2014

Primary Completion Date

March 9, 2021

Study Completion Date

March 9, 2021

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Gefitinib

Gefitinib QD

DRUG

MEDI4736

MEDI4736 IV Q2W

Trial Locations (7)

33612

Research Site, Tampa

77030

Research Site, Houston

98109

Research Site, Seattle

104-0045

Research Site, Chūōku

791-0280

Research Site, Matsuyama

03080

Research Site, Seoul

05505

Research Site, Seoul

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

MedImmune LLC

INDUSTRY